

Amniotic Membrane Market Is Forecasted To Expand At 9.9% CAGR To Reach US\$ 7.55 Billion By 2034, Fact.MR Report

Amniotic Membranes Widely Used in Eye Surgeries to Promote Swift Healing and Quick Recovery: Fact. MR Report

ROCKVILLE, MD, UNITED STATES, July 11, 2024 /EINPresswire.com/ --

According to a recently updated industry report by Fact.MR, the global [amniotic membrane market](#) is set to reach US\$ 2.95 billion in 2024 and further expand at 9.9% CAGR from 2024 to 2034.

An amniotic membrane graft is a surgical procedure that uses a thin, transparent membrane derived from the placenta's innermost layer (amniotic membrane) as a graft or patch to treat a variety of medical conditions. Amniotic membrane grafts in ophthalmic surgery enable the treatment of ocular surface disorders, corneal defects, conjunctival reconstruction, and other eye-related conditions.

Get Free Sample Copy of This Report:

https://www.factmr.com/connectus/sample?flag=S&rep_id=7125

Rapid recovery properties of tissue-based products in ophthalmic surgeries are projected to drive the growth of the amniotic membrane market during the forecast period. Furthermore, demand for cosmetic surgeries is rising at a significant pace. Recent advancements in amniotic membrane technology include cryopreservation, bioengineering, tissue engineering, biocompatible scaffolds, amniotic fluid-derived products, and topical applications. These advancements enable improved tissue repair, regeneration, and therapeutic modulation.



Technological advancements in the surgical sector, as well as increased use of amniotic membranes in regenerative medicine, are expected to boost market expansion. Amniotic tissue grafts aid in wound healing during complex surgeries and are therefore widely used by surgeons.

Key Takeaways from Market Study:

The global market for amniotic membranes is projected to expand swiftly at a CAGR of 9.9% from 2024 to 2034. By the end of 2034, the market is forecasted to climb to a value of US\$ 7.55 billion.

The market in the United States is poised to reach a value of US\$ 902.2 million in 2024. China is set to occupy 44.7% share of the East Asia market in 2024.

Revenue from the sales of amniotic membranes in Japan is estimated to reach US\$ 163.2 million in 2024. The North American market is forecasted to expand at a CAGR of 12% through 2034.

“Diverse properties of amniotic membranes, including their ability to repair tissue damage and anti-inflammatory characteristics are boosting their application in severe dry eye cases and other critical conditions,” says a Fact.MR analyst.

Key Companies Profiled are Alliqua BioMedical Inc.; Amnio Technology LLC; Applied Biologics LLC; Human Regenerative Technologies LLC; DermaSciences; Katena Products Inc.; MiMedx Group Inc.; Skye Biologics Inc.; Amnioc Medical Inc.; Integra LifeSciences Corporation; MiMedx Group, Inc.; Skye Biologics Holdings, LLC.

High Awareness of Therapeutic Benefits of Amniotic Membranes in Europe

Europe is emerging as a lucrative market for amniotic membrane providers driven by adoption of universal healthcare systems.

According to the World Health Organization (WHO), diabetes, cancer, cardiovascular disease, and chronic respiratory ailments account for approximately 86% of all deaths in Europe.

Healthcare providers, policymakers, and patients are increasingly recognizing the therapeutic potential of amniotic membrane-based therapies in addressing a wide range of medical conditions. As a result, demand for effective methods to reduce fatalities and combat diseases is driving market growth.

Competitive Landscape

Major participants in the amniotic membrane industry are spending more on R&D, which enables them to produce cutting-edge goods that satisfy consumer needs. Several clinical trials

conducted aid corporations in their efforts to obtain product approvals.

Amnio Technology unveiled two brand-new membrane products in February 2022: the Dual-Layer PalinGen X-Membrane and the PalinGen Dual-Layer Membrane. Similar to the other PalinGen membrane products, these novel allografts are homologous compatible, minimally processed, and chorion-free. These allografts have two outer epithelial surfaces and a single application direction because to their dual-layer construction.

A prominent manufacturer of placental biologics, MiMedx Group, Inc., introduced Amnioeffect in September 2022. It consists of three layers: an intermediate membrane layer, a chorion layer, and an amnion layer.

Get Customization on this Report for Specific Research Solutions:

https://www.factmr.com/connectus/sample?flag=S&rep_id=7125

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the amniotic membrane market for 2018 to 2023 and forecast statistics for 2024 to 2034.

The study divulges the amniotic membrane market based on product (cryopreserved amniotic membranes, dehydrated amniotic membranes), application (surgical wounds, ophthalmology, others), and end user (hospitals, ambulatory surgical centers, specialty clinics, research & academic institutes) across six major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and MEA).

Explore More Related Studies Published by Fact.MR Research:

[Transfer Membrane Market](#): stands at US\$ 191.1 million and is predicted to reach a market valuation of US\$ 226.3 million by the end of 2032.

[Wound Healing Assessment Market](#): size is estimated to be worth US\$ 106.8 million in 2024 and reach US\$ 176.8 million by the end of 2034, expanding at a CAGR of 5.2%.

About Fact.MR:

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

Contact:

US Sales Office

11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: sales@factmr.com

S. N. Jha
Fact.MR
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/726775552>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.